MINNEAPOLIS, July 9 /PRNewswire-FirstCall/ -- ATS Medical, Inc.
(Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery
products and services, today announced it has obtained new in vivo data to
support the outstanding wear characteristics of the ATS Open Pivot(R)
Mechanical Heart Valve.
The first ATS Open Pivot valve was implanted in Lausanne, Switzerland on
May 4, 1992 by Professor H. Sadeghi and Dr. Demetre Nicoloff. The patient was
70 years old at the time of his surgery and enjoyed another active 15 years
with his ATS Open Pivot valve. He recently passed away from non-valve related
causes and his physician and family permitted the explantation of his Open
Pivot valve for scientific analysis. Scanning electronic microscopy and laser
profilometry were used to quantify the wear on the carbon portion of the
valve. After 15 years of use and an estimated 560 million opening and closing
cycles, the Open Pivot valve displayed no detectable wear.
"We appreciate the willingness of Professor Sadeghi and the patient's
family to allow ATS the opportunity to examine the first implanted Open Pivot
valve. Their generous contribution has provided valuable data that validates
the excellent durability of the ATS valve and is a strong testament of its
clinical benefits for potential patients and their physicians," stated Michael
Dale, Chairman, President, and CEO of ATS Medical.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on
cardiac surgery. The Company, global in scope, is headquartered in
Minneapolis, Minnesota. More than 150,000 ATS Open Pivot(R) Heart Valves,
which utilize a unique pivot design resulting in exceptional performance and
low risk profile, have been implanted in patients worldwide. The ATS 3f(R)
brand encompasses multiple tissue heart valve product offerings at varying
steps from market introductions to clinical trials to development projects
that incorporate less invasive valve replacement technology. ATS Medical's
focus on serving the cardiac surgery community is further strengthened by
offerings that include ATS Simulus(R) annuloplasty products for heart valve
repair and ATS CryoMaze(TM) surgical ablation products. The ATS Medical web
site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include
statements regarding intent, belief or current expectations of the Company and
its management. Actual results could differ materially from those projected in
the forward-looking statements as a result of a number of important factors,
including the results of clinical trials, the timing of regulatory approvals,
the integration of 3f Therapeutics and the surgical cryoablation business of
CryoCath Technologies, Inc., regulatory actions, competition, pricing
pressures, supplier actions and management of growth. For a discussion of
these and other risks and uncertainties that could affect the Company's
activities and results, please refer to the Company's filings with the
Securities and Exchange Commission, including its Form 10-K for the year ended
December 31, 2007 and its most recent quarterly report on Form 10-Q.
SOURCE ATS Medical, Inc.
Michael Dale, President|CEO, +1-763-553-7736,
Michael Kramer, CFO, +1-763-557-2222,
or Investors, Doug Sherk, Jenifer
Kirtland, or Donald Takaya, +1-415-896-6820,
or Media, Steve DiMattia,
all for ATS Medical, Inc.
Web site: http://www.atsmedical.com